Tech Center 1600 • Art Units: 1642 1652 1671
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17775446 | BIPARATOPIC CD73 ANTIBODIES | Final Rejection | GENZYME CORPORATION |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | Non-Final OA | Xencor, Inc. |
| 17775233 | TARGETING CIRCULAR PCMTD1 IN LEUKEMIAS WITH P53 MUTATIONS AND/OR BCR/ABL FUSIONS | Non-Final OA | Ohio State Innovation Foundation |
| 19328820 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | Non-Final OA | Genentech, Inc. |
| 17937102 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | Non-Final OA | Genentech, Inc. |
| 18284590 | MODULATING PRODUCT QUALITY OF ASYMMETRIC MULTISPECIFIC ANTIBODIES THROUGH THE USE OF TEMPERATURE | Non-Final OA | AMGEN INC. |
| 18457729 | BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP | Non-Final OA | Hoffmann-La Roche Inc. |
| 18238153 | CONTORSBODY - A SINGLE CHAIN TARGET BINDER | Final Rejection | Hoffmann-La Roche Inc. |
| 17763614 | COMPOSITE BIOMARKER FOR CANCER THERAPY | Non-Final OA | Bristol-Myers Squibb Company |
| 18547644 | COMPOSITIONS AND METHODS FOR STABILIZATION OF ALLOSTERIC PROTEINS | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 18297979 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18193917 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17608891 | METHODS FOR PREDICTING DRUG RESPONSIVENESS IN SAMPLES FROM CANCER SUBJECTS | Final Rejection | Board of Regents, The University of Texas System |
| 18030223 | ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17905043 | COMBINED ANTI-CYTOKINE THERAPY TO REDUCE METASTATIC CANCER | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 16956537 | BAFF THERAPY TO PROMOTE ANTI-TUMOR IMMUNITY | Final Rejection | The Johns Hopkins University |
| 16479652 | MINI-CANCERS UTILIZATION FOR PERSONALIZED CANCER DRUG REGIMENS | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18256222 | Agent for Preventing or Treating Frontotemporal Lobar Degeneration | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 18309697 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | Final Rejection | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY |
| 17294401 | COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17926235 | TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | Non-Final OA | ASTRAZENECA AB |
| 17657537 | PD-L1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | Final Rejection | PRELUDE CORPORATION |
| 17995089 | ANTI-CD33 ANTIBODIES AND USES THEREOF | Non-Final OA | Fred Hutchinson Cancer Center |
| 17918479 | TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18010580 | BIOMARKER BASED PATIENT SELECTION FOR PROTEASOME INHIBITOR TREATMENT | Non-Final OA | University of Utah Research Foundation |
| 18055406 | TUMOR-INTRINSIC NLRP3 INFLAMMASOME SIGNALING PATHWAY AS A GENETIC AND FUNCTIONAL BIOMARKER FOR IMMUNOTHERAPY RESPONSE | Non-Final OA | Duke University |
| 18122194 | METHODS OF TREATING GLIOBLASTOMA | Final Rejection | Ramot at Tel-Aviv University Ltd. |
| 17666999 | METHODS FOR IDENTIFYING AND TREATING HIGH-PLASTICITY CELL STATE DRIVING TUMOR PROGRESSION IN LUNG CANCER | Non-Final OA | Memorial Hospital for Cancer and Allied Diseases |
| 18256556 | High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal Antibody | Non-Final OA | Albert Einstein College of Medicine |
| 18745729 | ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy